Cervical Lesion

3

Review clinical trials related to Cervical Lesion. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions

This is a single-center, Phase II interventional study evaluating secondary HPV vaccination after treatment of high-grade cervical lesions. The study aims to estimate the rate of HPV clearance within two years following an initial positive HPV control test in women over 45 years of age who are chronic HPV carriers and have undergone treatment for high-grade intraepithelial cervical lesions, and who receive HPV vaccination. The study includes two cohorts: 1. Eligible patients who consent to vaccination will participate in a prospective, single-center, single-arm, interventional clinical trial (Category 2). 2. Non-vaccinated patients will be included in a non-interventional observational study, with no changes to their standard care.

Participants needed: 85
Trial details
Phase: Phase 2Age: 45+Biological sex: FemaleType: InterventionalSponsor: Centre Oscar LambretUpdated: Mar 18, 2026Locations: 1
Eligibility criteria

Female patient over 45 years old [+13]

Common exclusion criteria for the study (for both cohorts) [+7]

Status: Recruiting

Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors

The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy biopsy pathology results. At the same time, paraffin tissue specimens (remaining specimens after pathological diagnosis) from 100 cases of cervical neuroendocrine tumors from multiple centers across the country were collected to establish a cervical neuroendocrine tumor data follow-up database. Protein concentration and omics analysis were performed on the data results, to evaluate the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins, and to preliminarily explore its clinical application value.

Participants needed: 300
Trial details
Biological sex: FemaleType: ObservationalSponsor: Fujian Maternity and Child Health HospitalUpdated: Sep 19, 2024Locations: 9
Eligibility criteria

Patients diagnosed with cervical neuroendocrine carcinoma by histopathology [+1]

Patients who are not being treated in our hospital [+3]

Status: Recruiting

A Clinical Trial to Compare Lasotronix Alone or in Combination With CPP-ACP to Treat DH

Dentin hypersensitivity (DH) is defined as sharp pain of a shorter duration arise from exposed dentin in response to several chemicals and thermal or tactile stimuli that cannot be ascribed to other dental defects". DH has a prevalence rate ranging from 1.3% to 92.1%, commonly affecting old ages. The use of laser has opened new dimensions in the treatment of DH. To the author's knowledge, not much research work has been conducted using LASOTRONIX as a treatment modality with CPP-ACP. Therefore, this research aims to determine the effectiveness of Casein phospho peptide paste (CPP-ACP) used alone or combined with a diode laser (LASOTRONIX).

Participants needed: 120
Trial details
Age: 25-65Biological sex: AllType: InterventionalSponsor: Dow University of Health SciencesUpdated: Jul 26, 2024Locations: 1
Eligibility criteria

Patients of either gender, with ages between 25-65 years [+1]

History of desensitizing therapy on the affected tooth/teeth in last six months... [+4]